Genentech Oncology
Antibody drug conjugate (ADC) technology leverages the selectivity of monoclonal antibodies (MAbs) to offer novel possibilities to cancer patients.1 This approach has been utilized in the management of select hematologic malignancies and solid tumors.1,2
ADCs can be an effective and targeted vehicle designed to deliver potent cytotoxic agents directly to tumor cells through selective antibody binding.3
ADCs are a rational vehicle to exploit the internalization of monoclonal antibodies for the delivery of a potent cytotoxic agent inside target cells.3,4
This technology may be applied as foundational ADC therapy or as a potential complement to existing treatment approaches.1
Genentech is currently investigating the potential of using an ADC with other agents such as traditional monoclonal antibodies, including PD-L1 inhibitors, small molecules, and T-cell bispecific antibodies.5,6
Diamantis N, Banerji U. Br J Cancer. 2016;114:362-367. PMID: 26742008
Diamantis N, Banerji U. Br J Cancer. 2016;114:362-367. PMID: 26742008
Pfeifer M, Zheng B, Erdmann T, et al. Leukemia. 2015;29:1578-1586. PMID: 25708834
Pfeifer M, Zheng B, Erdmann T, et al. Leukemia. 2015;29:1578-1586. PMID: 25708834
Peters C, Brown S. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432
Peters C, Brown S. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432
Polson AG, Yu S-F, Elkins K, et al. Blood. 2007;110:616-623. PMID: 17374736
Polson AG, Yu S-F, Elkins K, et al. Blood. 2007;110:616-623. PMID: 17374736
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf
US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671018. Accessed May 26, 2022.
US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671018. Accessed May 26, 2022.
Learn more about the importance of oncologic biomarkers and what they can tell you.
Learn more about how cancer avoids immune response.
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.